Physician profile
Gene Im
NPI 1730497454
$14,951.85
in general payments reported to CMS, 2019-2025
9 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.86 · 2021: $20.11 · 2023: $26.87 · 2024: $14K · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,143 · Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,981.25 |
| Travel and Lodging | $1,142.59 |
| Food and Beverage | $791.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14,310.02 | 2024 | |
| Madrigal Pharmaceuticals | $147.40 | 2025 | Rezdiffra |
| Cook Medical LLC | $139.04 | 2024 | Echotip Insight |
| Ipsen Biopharmaceuticals, INC | $132.65 | 2024-2025 | Iqirvo |
| Abbvie INC. | $112.66 | 2025 | |
| Gilead Sciences, INC. | $36.97 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.08 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.87 | 2023 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2025 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.